title: Pilocarpine-induced status epilepticus: monoamine level, muscarinic and dopaminergic receptors alterations in striatum of young rats.
abstract: Behavioural changes, muscarinic and dopaminergic receptors density and levels of monoamines were measured in striatum of rats after pilocarpine-induced status epilepticus (SE). Wistar rats at the age of 21 days were treated with pilocarpine (400mg/kg; subcutaneously) whilst the control group was treated with 0.9% saline (s.c.). Both groups were sacrificed 1h following the treatment. SE induced a muscarinic receptor downregulation of 64% in pilocarpine group. This effect was also observed to be 57% in D(1) and 32% in D(2). In the dissociation constant (K(d)) values in muscarinic and D(1) receptor no alterations were verified. On the other hand, the K(d) value for D(2) was observed to increase 41%. High performance liquid chromatography determinations showed 63, 35, 77 and 64% decreases in dopamine, 3-methoxy-phenylacetic acid, serotonin and 5-hydroxyindoleacetic acid contents, respectively. The homovanilic acid level was verified to increase 119%. The noradrenaline content was unaltered. A direct evidence of monoamine levels alterations can be verified during seizure activity and receptor density changes appear to occur in an accentuated way in immature brain during the estabilishment of SE induced by pilocarpine.
authors.affiliation: Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, Fortaleza, CE, Brazil.
authors.forename: V S
authors.initials: VS
authors.lastname: Nascimento
authors.forename: A A
authors.initials: AA
authors.lastname: Oliveira
authors.forename: R M
authors.initials: RM
authors.lastname: Freitas
authors.forename: F C F
authors.initials: FC
authors.lastname: Sousa
authors.forename: S M M
authors.initials: SM
authors.lastname: Vasconcelos
authors.forename: G S B
authors.initials: GS
authors.lastname: Viana
authors.forename: M M F
authors.initials: MM
authors.lastname: Fonteles
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001522:Behavior, Animal / Q000187:drug effects; D001552:Benzazepines / Q000493:pharmacokinetics; D015306:Biogenic Monoamines / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D018492:Dopamine Antagonists / Q000493:pharmacokinetics; D005786:Gene Expression Regulation / Q000187:drug effects; D008297:Male; D019832:N-Methylscopolamine / Q000493:pharmacokinetics; D010862:Pilocarpine; D011869:Radioligand Assay / Q000379:methods; D051381:Rats; D017208:Rats, Wistar; D011954:Receptors, Dopamine / Q000145:classification / Q000378:metabolism*; D011976:Receptors, Muscarinic / Q000145:classification / Q000378:metabolism*; D013226:Status Epilepticus / Q000139:chemically induced* / Q000378:metabolism; D014316:Tritium / Q000493:pharmacokinetics
chemical_list: D001552:Benzazepines; D015306:Biogenic Monoamines; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D011976:Receptors, Muscarinic; D010862:Pilocarpine; D014316:Tritium; D019832:N-Methylscopolamine